Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells

Anticancer Res. 2009 Jan;29(1):139-44.

Abstract

Background: The mechanisms of estrogen insensitivity or estrogen resistance in ovarian cancer cells are not known. Studies on regulation of the estrogen receptor (ER) gene have suggested a role for epigenetics in silencing ER expression.

Materials and methods: Cells from insensitive ovarian cancer cells, SKOV3 and HEY, were cultured with and without the DNA methyltransferase (DNMT) inhibitor, 5-aza-2'-deoxycytidine (AzaC) and the histone deacetylase (HDAC) inhibitor, trichostatin (TSA). ERbeta promoter methylation was examined using bisulfite sequencing. RNA was collected for oligonucleotide array studies.

Results: Cell type-specific ERbeta promoter methylation was found as well as relative hypomethylation of the ERbeta promoter in SKOV3 compared to HEY cells. Preferential demethylation of specific CpGs by different treatments was found. AzaC and TSA resulted in significant tumor growth inhibition and alterations in expression of numerous genes.

Conclusion: The ERbeta promoter is differentially methylated in ovarian cancer cells. Moreover, AzaC and TSA can inhibit ovarian cancer cell growth.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Azacitidine / analogs & derivatives
  • Azacitidine / pharmacology
  • Cell Growth Processes / drug effects
  • Cell Growth Processes / physiology
  • Cell Line, Tumor
  • DNA (Cytosine-5-)-Methyltransferases / antagonists & inhibitors
  • DNA (Cytosine-5-)-Methyltransferases / metabolism
  • DNA Methylation
  • Decitabine
  • Enzyme Inhibitors / pharmacology
  • Estrogen Receptor beta / genetics*
  • Female
  • Histone Acetyltransferases / antagonists & inhibitors
  • Histone Acetyltransferases / metabolism
  • Humans
  • Hydroxamic Acids / pharmacology
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / pathology
  • Promoter Regions, Genetic

Substances

  • Enzyme Inhibitors
  • Estrogen Receptor beta
  • Hydroxamic Acids
  • trichostatin A
  • Decitabine
  • DNA (Cytosine-5-)-Methyltransferases
  • Histone Acetyltransferases
  • Azacitidine